Medication info
Neosita Tablet 50 mg (Sitagliptin Hydrochloride Hydrate)

Neosita Tablet 50 mg (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Nokshikja Co., Ltd.
Appearance
A film-coated tablet that is light apricot in color with a round shape and both sides being convex.
Packaging
28 tablets/box [(14 tablets/PTPX2)]
Approval status
Active

MFDS item code 202101813 · Approved 2021.02.24 · Insurance code 643606110

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken regardless of meals. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, section 5. General Precautions). Because dose adjustment is required according to renal function, evaluation of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Nokshikja Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control for patients with type 2 diabetes
View approved original text

This medication is used in conjunction with dietary therapy and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. It can be used alone, but when initial blood sugar control is difficult, it may be combined with metformin. Additionally, it can be administered in combination when there is insufficient effect from monotherapy with sulfonylurea, metformin, thiazolidinedione, or insulin. It also helps in cases where blood sugar control is challenging despite various medications. This medication is effective in improving blood sugar control.

How to take

Adult dose

This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken regardless of meals. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, section 5. General Precautions). Because dose adjustment is required according to renal function, evaluation of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication may cause severe allergic reactions after administration; thus, if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck develop, discontinue use immediately and consult a doctor. Acute pancreatitis, a serious inflammation of the pancreas, may occur. If symptoms such as abdominal pain, vomiting, or severe abdominal discomfort appear, seek medical attention immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Patients who have had an allergic reaction to this medication or its components should avoid its use. Patients with reduced kidney function may experience slower excretion of this medication, and dosage adjustment should be made according to a doctor's guidance with regular kidney function tests. Commonly reported side effects in clinical trials include upper respiratory tract infections, nasopharyngitis, headaches, and diarrhea. Hypoglycemic symptoms may also occur, so blood sugar management should be carefully monitored. When taken with insulin or sulfonylurea, the risk of hypoglycemia may increase, requiring dosage adjustments of these medications. Severe joint pain may occur; consider consulting a doctor about discontinuing medication if joint pain worsens. If symptoms such as skin blisters or ulceration appear, notify a doctor immediately for appropriate diagnosis and treatment. The safety of this medication in pregnant women has not been established, so its use is not recommended. Nursing mothers are also advised not to take this medication. Safety has not been confirmed in children and adolescents, so it should not be used in patients under 18 years of age. Elderly patients may have a risk of reduced kidney function, so dosage adjustment and monitoring of kidney function are necessary. In cases of overdose, general symptomatic treatment should be administered, and hemodialysis may be used to remove some of the medication if necessary. This medication generally has no significant drug interactions when used in conjunction with other diabetes medications or cardiovascular drugs, but it is important to consult a doctor or pharmacist about any other medications being taken.

Side effects

  • Severe allergic reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory infection
  • nasopharyngitis
  • headache
  • diarrhea
Show 29 more
  • abdominal pain
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • pneumonia
  • diabetic complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and it is recommended to keep it at room temperature between 1°C and 30°C. Proper storage will maintain the effectiveness and safety of the medication.

Appearance and packaging

Appearance

A film-coated tablet that is light apricot in color with a round shape and both sides being convex.

Package unit

28 tablets/box [(14 tablets/PTPX2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.